New Vaccine Partnership With GSK Could Act As Lifeline For Chinese Biotech Firm Neptunus, Which Has Been Trapped In Troubled Financial Seas
This article was originally published in PharmAsia News
Executive Summary
BEIJING - A new vaccine joint venture with the United Kingdom's GlaxoSmithKline could become a lifesaver for the Chinese biologics outfit Shenzhen Neptunus Interlong Bio-Technique Co., which has been fighting to stay afloat amid a maelstrom of earnings losses, staff layoffs and a partial halt in production